Literature DB >> 22045835

Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis.

Xia Sheng1, Michael J Murphy, Thomas M Macdonald, Li Wei.   

Abstract

OBJECTIVE: There is increasing prevalence of hypercholesterolemia among patients with osteoarthritis (OA) and rheumatoid arthritis (RA). We examined the effectiveness of statins on total cholesterol (TC), cardiovascular (CV) morbidity, and mortality in patients with OA or RA.
METHODS: A population-based cohort study was done using a record-linkage database in Tayside, Scotland. In total, 2024 OA or RA patients who had at least 2 separate TC measurements between 1993 and 2007 were studied. They were categorized into statin-exposed and statin-unexposed groups according to statin use status during followup. The main outcomes were TC concentration change from baseline, CV events, and all-cause mortality during the followup. Multivariate Cox regression models with a time-dependent variable for statins were employed to assess the risk of outcomes.
RESULTS: Statin-associated TC concentrations in OA decreased by 15% in patients without CV disease (primary prevention, n = 1269) and 7% in patients with CV disease (secondary prevention, n = 247) from baseline of 5.30 mmol/l and 4.54 mmol/l, respectively. Correspondingly, in RA TC was reduced by 16% (n = 430) and 15% (n = 78) with baselines of 5.54 mmol/l and 4.95 mmol/l. In primary prevention, statins were associated with reduced CV events and all-cause mortality in RA patients [adjusted HR 0.45 (95% CI 0.20-0.98) and 0.43 (95% CI 0.20-0.92), respectively] and all-cause mortality in OA patients [adjusted HR 0.43 (95% CI 0.25-0.72)]. Statins were not associated with reduced risk of CV events or all-cause mortality in the secondary prevention of RA or OA patients [adjusted HR 0.68 (95% CI 0.30-1.54) and 0.52 (95% CI 0.20-1.34) for OA patients, and HR 0.58 (95% CI 0.07-4.79) and 0.79 (95% CI 0.18-3.53) for RA patients].
CONCLUSION: Statins reduced TC concentrations between 7% and 16% in patients with OA or RA. Statins were associated with reduced CV events and mortality in RA and mortality in OA in primary prevention.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22045835     DOI: 10.3899/jrheum.110318

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

1.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

2.  Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis.

Authors:  Michelly Cristiny Pereira; Pablo Ramon Gualberto Cardoso; Laurindo Ferreira Da Rocha; Moacyr Jesus Barreto Melo Rêgo; Sayonara Maria Calado Gonçalves; Flaviana Alves Santos; Marina Rocha Galdino-Pitta; Andréa Tavares Dantas; Ângela Luzia Branco Pinto Duarte; Maira Galdino Da Rocha Pitta
Journal:  Inflamm Res       Date:  2014-01-14       Impact factor: 4.575

Review 3.  Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus.

Authors:  J Michelle Kahlenberg; Mariana J Kaplan
Journal:  Annu Rev Med       Date:  2012-09-27       Impact factor: 13.739

Review 4.  Managing cardiovascular risk in patients with inflammatory arthritis: practical considerations.

Authors:  Anne Tournadre; Sylvain Mathieu; Martin Soubrier
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-09-05       Impact factor: 5.346

5.  Impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis versus non-rheumatoid arthritis subjects: results from a population-based study.

Authors:  Elena Myasoedova; Sherine E Gabriel; Abigail B Green; Eric L Matteson; Cynthia S Crowson
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-10       Impact factor: 4.794

6.  [Risk of atherosclerosis mediated by inflammation in rheumatoid arthritis].

Authors:  S Kleinert; K Krueger; S Störk
Journal:  Z Rheumatol       Date:  2012-12       Impact factor: 1.372

Review 7.  Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents.

Authors:  Federico Carbone; Aldo Bonaventura; Luca Liberale; Sabrina Paolino; Francesco Torre; Franco Dallegri; Fabrizio Montecucco; Maurizio Cutolo
Journal:  Clin Rev Allergy Immunol       Date:  2020-02       Impact factor: 8.667

8.  Statin use and mortality in rheumatoid arthritis: a general population-based cohort study.

Authors:  Sara R Schoenfeld; Leo Lu; Sharan K Rai; John D Seeger; Yuqing Zhang; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2015-08-05       Impact factor: 19.103

Review 9.  Rheumatoid arthritis and cardiovascular disease: an update on treatment issues.

Authors:  Medha Barbhaiya; Daniel H Solomon
Journal:  Curr Opin Rheumatol       Date:  2013-05       Impact factor: 5.006

Review 10.  Cardiovascular disease and rheumatoid arthritis: an update.

Authors:  Christina Charles-Schoeman
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.